Eversana adds more field sales support

Article

Latest acquisition brings commercial assets from Mission Pharmacal

One of the things Facebook has been famous for is its ethos to “move fast and break things;” at Eversana, that theme could be modified to “move fast and build things.” In rapid succession since its founding less than two years ago, it acquired seven companies involved in a variety of services for pharma clients; now it is adding an eighth: Alamo Pharma Services, Inc., and BexR Telesales, both former units of Mission Pharmacal, a pharma and healthcare products company. The new resources provide added field sales, telesales, reimbursement specialists and related commercialization resources to Eversana’s existing assets in sales, marketing and patient support.

A few weeks prior to the Mission Pharmacal announcement, Eversana forged a partnership with OptimizRx, which connects copay coupons and other pharma-originated information to patients through electronic health-record (EHR) systems.

With the current expansion, Eversana CEO Jim Lang says that “Field solutions are rapidly becoming more sophisticated, clinically oriented and data-driven. Adding Alamo’s leadership in this space to our full commercial platform creates a seamless experience where we can both describe value and capture the data to measure value for all patients, payers, and providers.” Peter Marchesini, COO of Alamo Pharma Services, is coming onboard as president, Field Solutions.

Eversana’s news releases characterize the company as the “leading independent provider of global services to life sciences,” which raises the question, independent of what? An indication is the company’s earlier announcement this year of executive appointments from AmerisourceBergen, Cardinal Health and inventive Health (now Syneos Health), combined with chairman Mark Therier, former OptumRx CEO. Thus, Eversana is positioning itself as offering services similar to, but independent of, the major wholesaler/distributors and PBMs in the US.

Related Content
© 2024 MJH Life Sciences

All rights reserved.